Does DAROLUTAMIDE Cause Hormone-refractory prostate cancer? 104 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 104 reports of Hormone-refractory prostate cancer have been filed in association with DAROLUTAMIDE (NUBEQA). This represents 3.2% of all adverse event reports for DAROLUTAMIDE.
104
Reports of Hormone-refractory prostate cancer with DAROLUTAMIDE
3.2%
of all DAROLUTAMIDE reports
9
Deaths
4
Hospitalizations
How Dangerous Is Hormone-refractory prostate cancer From DAROLUTAMIDE?
Of the 104 reports, 9 (8.7%) resulted in death, 4 (3.8%) required hospitalization.
Is Hormone-refractory prostate cancer Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DAROLUTAMIDE. However, 104 reports have been filed with the FAERS database.
What Other Side Effects Does DAROLUTAMIDE Cause?
Fatigue (384)
Death (361)
Hot flush (203)
Asthenia (173)
Prostatic specific antigen increased (156)
Off label use (133)
Neuropathy peripheral (127)
Diarrhoea (122)
Dizziness (122)
Rash (116)
What Other Drugs Cause Hormone-refractory prostate cancer?
RADIUM RA-223 DICHLORIDE (441)
LEUPROLIDE (180)
DOCETAXEL (123)
ENZALUTAMIDE (120)
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (110)
ABIRATERONE (83)
PREDNISONE (58)
CABAZITAXEL (57)
BICALUTAMIDE (50)
CARBOPLATIN (27)
Which DAROLUTAMIDE Alternatives Have Lower Hormone-refractory prostate cancer Risk?
DAROLUTAMIDE vs DARUNAVIR
DAROLUTAMIDE vs DARUNAVIR ETHANOLATE
DAROLUTAMIDE vs DARUNAVIR\RITONAVIR
DAROLUTAMIDE vs DASABUVIR
DAROLUTAMIDE vs DASABUVIR\OMBITASVIR HEMINONAHYDRATE\PARITAPREVIR\RITONAVIR